CMV immunity test to guide antiviral prevention after transplant
Treatments studied
Part of Blood & lymphatic, Immune system & allergy, Infections clinical trials.
This trial uses a blood test to measure your immune system's ability to fight CMV, a common virus after transplant. The results will help your doctors decide if you can safely stop taking the antiviral medication letermovir earlier to avoid unnecessary side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a stem cell transplant from a donor (allogeneic).
- You had CMV before your transplant or are at risk for it.
- You are currently taking letermovir and are around day 90 after your transplant.
- You are considered at high risk for CMV coming back after day 100 (for example, because of graft-versus-host disease, a mismatched donor, or certain treatments).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well your immune system fights CMV (a common virus) after you stop taking a preventive medicine called Letermovir. It aims to see if your immune recovery can predict later CMV infections.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
This study tests if doctors can safely stop the anti-CMV drug letermovir earlier in stem cell transplant patients who have recovered their immune system. It focuses on patients who are at high risk for CMV but currently have no active infection.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This trial tests whether the medicine letermovir can prevent a common virus (CMV) from coming back after an allogeneic stem cell transplant in children. It may help lower the risk of CMV infection during the vulnerable period right after transplant.
Hear when a new Hematopoietic Cell Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.